A meta-analysis of over 7,500 patients found that roughly 34% of people diagnosed with cannabis-induced psychosis later developed schizophrenia spectrum disorder, and about 11% developed bipolar disorder.
Psychiatrists treating psychotic episodes, emergency physicians evaluating cannabis-related psychosis, patients and families navigating a first psychotic episode.
What the researchers found
Pooling data from 13 studies with a total of 7,515 patients diagnosed with cannabis-induced psychosis, this meta-analysis calculated the rates at which these individuals later received diagnoses of schizophrenia spectrum disorder or bipolar disorder.
The conversion rates were substantial. Approximately one-third of patients with cannabis-induced psychosis eventually received a schizophrenia spectrum diagnosis, while about one in ten was later diagnosed with bipolar disorder. The 16 outcomes reported across the 13 studies showed consistent patterns despite variation in study design, follow-up periods, and geographic locations.
Meta-regression analyses explored what predicted higher conversion rates, looking for factors that distinguished patients who went on to develop chronic psychotic illness from those whose psychosis resolved without recurrence.
Why it matters
Distinguishing cannabis-induced psychosis from the onset of a primary psychotic disorder is one of the most consequential diagnostic challenges in psychiatry. This meta-analysis quantifies the stakes: about a third of cannabis-induced psychosis cases may actually be the first presentation of schizophrenia spectrum illness. That finding has direct implications for how aggressively clinicians should monitor and treat patients after a cannabis-induced psychotic episode.
The numbers in context
13 studies, 7,515 patients with cannabis-induced psychosis. 16 outcomes reported. Approximately 34% later diagnosed with schizophrenia spectrum disorder. Approximately 11% later diagnosed with bipolar disorder. Combined conversion rate to either condition: roughly 40–45%.
How the study worked
Systematic review and meta-analysis searching Medline, Embase, Web of Science, Google Scholar, and PsychInfo through January 2025. Included studies reporting on patients with cannabis-induced psychosis who were followed for subsequent schizophrenia spectrum or bipolar disorder diagnoses. Quality assessed using modified Newcastle-Ottawa scale. Random-effects meta-analyses calculated pooled prevalence; meta-regressions identified predictors.
Who was studied
13 studies (N=7,515 patients with cannabis-induced psychosis)
What this study cannot tell us
Observational studies with variable follow-up periods — some patients may convert after the study period ends, meaning these rates could be underestimates. Diagnosis of cannabis-induced psychosis vs. primary psychotic disorder is inherently difficult at first presentation. Studies could not control for all confounders (genetics, polysubstance use, premorbid function). Publication bias may affect results.
How to read the evidence
Meta-analysis of 13 observational studies with over 7,500 patients — strong evidence for the conversion rate estimate, though the underlying studies have inherent diagnostic challenges.
When this study was published
Published in 2026 with literature search through January 2025, representing the most current pooled estimate of psychosis-to-schizophrenia conversion rates.
The bigger picture
This meta-analysis strengthens the evidence linking cannabis to psychotic disorders (connecting to RTHC-00163, RTHC-00193, RTHC-00201, RTHC-00202, RTHC-00203, RTHC-00215). The ~34% conversion rate to schizophrenia is higher than the rate reported for psychosis from other substances, suggesting something specific about the cannabis-psychosis relationship rather than a generic substance-triggered vulnerability. The placental marker study (RTHC-00254) adds a possible prenatal dimension to this story.
Replication
Not stated in abstract.
Funding
Not reported in abstract.
Conflicts of interest
Not reported in abstract.
Questions still open
- Can clinical features at first psychotic presentation predict which patients will convert to schizophrenia? Would earlier or more sustained treatment after cannabis-induced psychosis reduce conversion rates? Does the potency or pattern of cannabis use before the psychotic episode predict conversion risk?
Read the original research
Prevalence of schizophrenia spectrum and bipolar disorder among patients with cannabis induced psychosis: a systematic review and meta-analysis.
BMC psychiatry, 26(1), 186
BMC Psychiatry is a well-regarded journal focusing on mental health research.
Citation
Javed, Mohammad Saad; El-Khoury, Rayane; Taha, Amr Ahmed; Reagu, Shuja Mohd. (2026). Prevalence of schizophrenia spectrum and bipolar disorder among patients with cannabis induced psychosis: a systematic review and meta-analysis.. BMC psychiatry, 26(1), 186. https://doi.org/10.1186/s12888-025-07382-2
Explore the wider topic
- How THC Affects Your Amygdala: The Brain's Threat Detector and Cannabis
- The Anandamide Connection: Your Body's Natural Bliss Molecule
- How Long for Cannabinoid Receptors to Return to Normal
- Cannabis and the Developing Brain: What Every Teenager (and Parent) Should Know
- Why Can't I Enjoy Anything Without Weed? The Science Behind It
- Dopamine Recovery After Quitting Weed: What the Science Says
- The Endocannabinoid System Explained Simply: What It Does and Why It Matters
- Your Endocannabinoid System Explained: Why Withdrawal Happens
- Your Nervous System After Quitting Weed: Fight or Flight
- Using Weed Under 18: What It Does to Your Developing Brain
- What THC Does to Your Brain: Why Withdrawal Happens
- THC and Your Prefrontal Cortex: What Cannabis Does to Your Decision-Making Brain
- Weed, Cortisol, and Stress: What Cannabis Does to Your Stress Hormones
- Weed and Memory: What the Science Says About THC and Your Hippocampus
- Weed and Motivation: Is Amotivational Syndrome Real?
- Weed and Your Nervous System: What THC Actually Does to Your Brain and Body
- How Weed Rewires Your Reward System (And How to Reset It)
- THC and Antipsychotics: A Complicated Relationship